Atrin Pharmaceuticals
Dr. Afargan has over 25 years of experience as a Senior Executive in Drug Discovery and Development. He served as CTO, CEO, and Chairman of several Biomed startups and public companies. Dr. Afargan is co-author of 7 INDs, 2 IDEs, and 2 505(B)2. Since 2012, Dr. Afargan has been the leading Lecturer of Pharmaceutical Sciences, School of Pharmacy, Hebrew University, Jerusalem, Israel. He is the innovator of the novel peptide-based drug Somatoprim® for the treatment of metabolic disorders and adenocarcinomas, and inventor of a series of issued and pending patents in innovative drug delivery systems, diagnostics, and new drug entities of small molecules and peptide-based drugs.
Dr. Afargan received a B.Sc. in Life Sciences, M.Sc. (S) in Molecular Biology, License in Pharmacy (B. Pharm.), M.Sc. Pharmaceutical Sciences and Ph.D. in Pharmaceutical and Life Sciences (Hebrew University, Israel).
This person is not in any teams
This person is not in any offices
Atrin Pharmaceuticals
Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.